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Patients with atrial fibrillation (AF) have a 5% annual
stroke risk depending on the presence of risk factors, i.e.
prior stroke or peripheral embolism, age, hypertension,
diabetes, impaired cardiac function, female gender, vascular
disease and, echocardiographically, presence of mitral
stenosis and moderate or severe left ventricular systolic
dysfunction [1, 2]. These risk factors are incorporated into
the previous and currently used risk scores, i.e. the
CHADS2 and CHA2DS2-VASc scores, respectively [1, 3].
Depending on these scores, it is decided whether to
prescribe vitamin K antagonists (VKA), aspirin, nothing,
or, in the future, the new oral anticoagulant drugs. Such
decision-making requires careful consideration of pros and
cons of anticoagulant therapy in the individual patient. On
the one hand, during VKA therapy major bleeding may
occur in up to 1.2–3.6% of patients yearly [4–7]. On the
other hand, even with VKA therapy the residual stroke or
systemic embolism rate in patients with AF remains
relatively high, with a yearly incidence ranging between
1.1% and 2.4%, indeed depending on the presence of
currently known risk factors [4, 6, 8].
Two decades ago, the Stroke Prevention in Atrial
Fibrillation III investigators found that transoesophageal
echocardiography (TEE) was a useful tool for refinement of
the above-mentioned risk scores [9]. Using TEE, they
showed that some of those patients classified as being at
moderate or high risk for thromboembolic complications
were actually at low risk. Furthermore, presence of stroke
risk factors during TEE identified those patients with the
highest risk of thromboembolic complications.
Since then, no prospective randomised trials have been
performed assessing the clinical safety and feasibility of TEE-
basedriskassessment.InthepresenteditionoftheNetherlands
Heart Journal, Dinh and colleagues present the design and
baseline data of the TEE-guIded randomized comparison of
AspiRin and vitamin K antagonists in patients with AFa n d
an increased risk of stroke (TIARA) pilot study [10]. It is
their hypothesis that a comprehensive strategy of TEE-based
aspirin treatment is safe and feasible in AF patients who are
eligible for VKA therapy on the basis of conventional risk
assessment. The primary objective was to show that in
patients who do not have predefined high-risk features on
TEE, TEE-based aspirin treatment is safe compared with
VKA therapy with respect to the composite endpoint of major
cardiovascular and cerebrovascular events. The second
objective was to assess whether TEE was feasible, i.e.
whether it was possible to assess all four TEE features of
increased stroke risk, being complex atheromatous plaques in
the thoracic aorta and signs of atrial stasis including dense
spontaneous echo contrast, thrombus, or low blood flow
velocities in the left atrial appendage. Patients were eligible if
they had documented paroxysmal or permanent AF and a
conventional indication for treatment with VKA. Patients
with a presumed very high risk of thromboembolic compli-
cations, i.e. previous stroke, systemic embolism, heart failure
or significantly impaired left ventricular systolic function,
mitral valve stenosis or hypertrophic cardiomyopathy, were
excluded. After TEE, patients were randomised to aspirin
100 mg daily or VKA therapy (target INR 2.5–3.5) if TEE
did not show high-risk abnormalities (i.e. one of the four TEE
features of high stroke risk mentioned above). They included
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DOI 10.1007/s12471-011-0119-z310 patients, of whom 69 were not eligible for randomisation
because of non-visualisation (n=5), technical failure (n=1),
or an abnormal TEE (n=63). The last-mentioned group
predominantly consisted of only one TEE abnormality, most
often being low left atrial appendage velocities and sponta-
neous echo contrast. A total of 241 patients (81%) were
randomised. Patients who could be randomised were youn-
ger, less often had coronary artery disease and a previous
transient ischaemic attack, had a higher ejection fraction, and
a lower CHADS2 score.
The authors are praised for their courage and effort in
performing this innovative study. Awaiting the safety
outcome, however, a number of limitations need to be
borne in mind. The present study is a small pilot study,
including 310 patients. Further support for the feasibility
and, if positive, for the safety of this strategy warrants
confirmation by a large-scale randomised study. Although
the study shows a favourable answer to their second
objective, i.e. feasibility of a TEE-based approach, it should
be kept in mind that all centres were highly trained in
performing TEE. This implies that such a strategy should
and can not be translated as a feasible strategy in all
cardiology centres. Before incorporation into new guide-
lines, it warrants further testing in a large number of
centres. Furthermore, the study was performed in AF
patients without a very high risk of stroke, with a mean
CHADS2 score of 1 which means that the results of the
TIARA study only apply to this patient category. Undeni-
ably, these are the patients in whom the pros and cons of
each treatment strategy are carefully weighed and dis-
cussed, and in whom decision-making is most troublesome.
Another point of concern is how to follow these patients. A
TEE without risk factors at one time point does not
implicate that the patient remains free of TEE risk factors
in the future. A new prospective study has to investigate
this issue. Finally, will the introduction of new oral
anticoagulant drugs such as dabigatran, rivaroxaban and
apixaban abolish the potential necessity of such a TEE-
guided strategy? [4, 5, 7] It is our belief that it will not.
Although VKA treatment and the new anticoagulant drugs
are more effective for the prevention of thromboembolic
complications as compared with aspirin, minor bleeding is
observed at a lower rate during aspirin use, even when
using the new generation of anticoagulant drugs [7].
We are looking forward to the safety results of the
TIARA study. If positive, the outcome warrants confirma-
tion in a large-scale prospective randomised study. Hope-
fully, we will be able to conduct such an innovative study
on how to improve therapy and outcome in AF patients in
the Netherlands.
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